Menu Search
Equities

Shilpa Medicare Ltd

SHILPAMED:NSI

Shilpa Medicare Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)912.80
  • Today's Change-30.20 / -3.20%
  • Shares traded944.63k
  • 1 Year change+146.04%
  • Beta0.8922
Data delayed at least 15 minutes, as of Nov 22 2024 10:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Shilpa Medicare Ltd grew revenues 9.66% from 10.50bn to 11.52bn while net income improved from a loss of 324.76m to a gain of 318.74m.
Gross margin66.38%
Net profit margin5.04%
Operating margin15.91%
Return on assets2.00%
Return on equity2.97%
Return on investment2.44%
More ▼

Cash flow in INRView more

In 2024, Shilpa Medicare Ltd increased its cash reserves by 59.53%, or 113.54m. The company earned 1.35bn from its operations for a Cash Flow Margin of 11.75%. In addition the company generated 467.75m cash from financing while 1.67bn was spent on investing.
Cash flow per share18.56
Price/Cash flow per share53.86
Book value per share238.05
Tangible book value per share184.39
More ▼

Balance sheet in INRView more

Shilpa Medicare Ltd has a Debt to Total Capital ratio of 17.46%, a lower figure than the previous year's 31.33%.
Current ratio1.74
Quick ratio1.08
Total debt/total equity0.2108
Total debt/total capital0.1746
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 198.15%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-23.23
EPS (TTM) vs
TTM 1 year ago		589.58
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.